Poolbeg Pharma upbeat on preliminary influenza drug results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-upbeat-on-preliminary-influenza-drug-results-758545326

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  264.14
-3.08 (-1.15%)
AAPL  300.23
+2.02 (0.68%)
AMD  424.10
-25.60 (-5.69%)
BAC  49.77
-0.08 (-0.16%)
GOOG  393.32
-3.85 (-0.97%)
META  614.23
-4.20 (-0.68%)
MSFT  421.92
+12.49 (3.05%)
NVDA  225.32
-10.42 (-4.42%)
ORCL  192.95
-2.66 (-1.36%)
TSLA  422.24
-21.06 (-4.75%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.